INVST’s Intellia Therapeutics NTLA Stock Holding History

INVST’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,047	Closed	-$177K	–	117
2019 Q4	$177K	Hold	12,047	–	–	0.07%	91
2019 Q3	$148K	Hold	12,047	–	–	0.07%	81
2019 Q2	$198K	Hold	12,047	–	–	0.1%	62
2019 Q1	$206K	Hold	12,047	–	–	0.1%	72
2018 Q4	$164K	Hold	12,047	–	–	0.09%	48
2018 Q3	$327K	Sell	12,047 -2,100	-15%	-$61.1K	0.17%	39
2018 Q2	$387K	Hold	14,147	–	–	0.23%	37
2018 Q1	$291K	Hold	14,147	–	–	0.19%	34
2017 Q4	$272K	Buy	+14,147	New	+$327K	0.2%	34

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

INVST's NTLA Position: Q1 2020 in Review

INVST sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 12,047 shares — an estimated $177K sold.

INVST first reported a position in NTLA in Q4 2017 and held it in 9 quarters. The position peaked at $387K in Q2 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

INVST reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
INVST sold 12,047 Intellia Therapeutics shares in Q1 2020, an estimated $177K.
INVST first reported a position in Intellia Therapeutics in Q4 2017 and held it in 9 quarters.
INVST's Intellia Therapeutics position peaked at $387K in Q2 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on INVST's 13F filing for Q1 2020, filed 23 Jun 2021.